PPH logo

PPH
VanEck Pharmaceutical ETF

202
Volume
207,637.00
52W High
$95.13
52W Low
$77.67
50D MA
$90.17
Prev Close
$92.43
Loading...
Loading...
News
all
press releases
4 Reasons to Buy Pharma ETFs Now for a Healthy Portfolio
Pharma's Trump-Pfizer boost sparks momentum, making ETFs PPH, IHE, PJP & XPH attractive for defensive, undervalued growth plays.
Zacks·22d ago
News Placeholder
More News
News Placeholder
White House Clarifies Recent Pharmaceutical Tariffs Exempt Countries with Trade Agreements: Report
According to a Reuters report cited by TradingView, a White House official stated that the Trump administration will honor the 15% pharmaceutical tariff cap for trade partners such as the EU and Japan, as outlined in existing agreements.
Stocktwits·1mo ago
News Placeholder
Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit
Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.
Zacks·1mo ago
News Placeholder
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
Sector ETF report for PPH
Zacks·1mo ago
News Placeholder
NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain
NVO rose about 4% on Aug. 18, 2025, after Wegovy won FDA approval as the first GLP-1 therapy for MASH, expanding its reach beyond obesity and diabetes. NVO-heavy ETFs like OZEM, THNR and PPH should benefit from this trend.
Zacks·2mo ago
News Placeholder
ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data
LLY tumbles despite solid Q2 results. ETFs like IHE, PPH, MEDX and MEDI with top exposure may offer buy-the-dip opportunities.
Zacks·3mo ago
News Placeholder
Trump To Issue 60-Day Warning Letters To Drugmakers Over Pricing
The U.S. President is expected to send out these letters through his social media platform, Truth Social.
Stocktwits·3mo ago
News Placeholder
AstraZeneca Q2 Beats On Cancer Drug Sales, Maintains Guidance — Shares Rise Premarket As Retail Cheers
Product sales rose 11% to $13.80 billion, or 95.4% of the total revenue, thanks to double-digit growth in Oncology and biopharmaceutical sales.
Stocktwits·3mo ago
News Placeholder
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
Sector ETF report for PPH
Zacks·3mo ago
News Placeholder
Merck’s Blockbuster Drug Keytruda Gets Canadian Regulator’s Approval For Treating Cervical Cancer: Retail Investors Appear Divided
Keytruda was first approved in Canada in 2015 and is approved for the treatment of several cancers affecting the bladder, lung, breast, head and neck, and other areas.
Stocktwits·3mo ago

Latest PPH News

View

Advertisement|Remove ads.

Advertisement|Remove ads.